Gupta S, Sharma A, Shukla A, Mishra A, Singh A
Invest New Drugs. 2025; .
PMID: 40014234
DOI: 10.1007/s10637-025-01513-y.
Yan M, Gong P, Li X, Huang H, Wei H
Front Endocrinol (Lausanne). 2024; 15:1467683.
PMID: 39610846
PMC: 11602317.
DOI: 10.3389/fendo.2024.1467683.
Speeckaert R, Belpaire A, Lambert J, Speeckaert M, van Geel N
Immune Netw. 2024; 24(5):e33.
PMID: 39513029
PMC: 11538609.
DOI: 10.4110/in.2024.24.e33.
Zhou D, Zi C, Gan G, Tang S, Chen Q
Front Endocrinol (Lausanne). 2024; 15:1341002.
PMID: 39086903
PMC: 11288873.
DOI: 10.3389/fendo.2024.1341002.
Nawaratne V, Sondhi A, Abdel-Wahab O, Taylor J
Clin Cancer Res. 2024; 30(11):2333-2341.
PMID: 38578606
PMC: 11147694.
DOI: 10.1158/1078-0432.CCR-23-0409.
The Inflammatory Contribution of B-Lymphocytes and Neutrophils in Progression to Osteoporosis.
Frase D, Lee C, Nachiappan C, Gupta R, Akkouch A
Cells. 2023; 12(13).
PMID: 37443778
PMC: 10340451.
DOI: 10.3390/cells12131744.
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.
Alu A, Lei H, Han X, Wei Y, Wei X
J Hematol Oncol. 2022; 15(1):138.
PMID: 36183125
PMC: 9526392.
DOI: 10.1186/s13045-022-01353-w.
Palmitoylation of the Alternative Amino Terminus of the BTK-C Isoform Controls Subcellular Distribution and Signaling.
Kokabee M, Wang X, Voorand E, Alin E, Kokabee L, Khan F
Cancer Genomics Proteomics. 2022; 19(4):415-427.
PMID: 35732327
PMC: 9247882.
DOI: 10.21873/cgp.20329.
Novel Bruton's Tyrosine Kinase (BTK) Substrates for Time-Resolved Luminescence Assays.
Widstrom N, Perez M, Pratt E, Heier J, Blankenhorn J, Breidenbach L
ACS Chem Biol. 2022; 17(6):1328-1333.
PMID: 35653784
PMC: 10041687.
DOI: 10.1021/acschembio.2c00106.
Differential Requirement of Vav Proteins for Btk-dependent and -Independent Signaling During B Cell Development.
Betzler A, Kieser S, Fiedler K, Laban S, Theodoraki M, Schuler P
Front Cell Dev Biol. 2022; 10:654181.
PMID: 35281114
PMC: 8904969.
DOI: 10.3389/fcell.2022.654181.
Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.
Mendes-Bastos P, Brasileiro A, Kolkhir P, Frischbutter S, Scheffel J, Monino-Romero S
Allergy. 2022; 77(8):2355-2366.
PMID: 35175630
PMC: 9545595.
DOI: 10.1111/all.15261.
Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA.
Meng A, Humeniuk R, Jurgensmeier J, Hsueh C, Matzkies F, Grant E
Clin Pharmacol Ther. 2021; 111(2):416-424.
PMID: 34623640
PMC: 9298258.
DOI: 10.1002/cpt.2439.
Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.
Neys S, Rip J, Hendriks R, Corneth O
Drugs. 2021; 81(14):1605-1626.
PMID: 34609725
PMC: 8491186.
DOI: 10.1007/s40265-021-01592-0.
Quantitative proteomics identifies PTP1B as modulator of B cell antigen receptor signaling.
Schwarz J, Grundmann L, Kokot T, Klasener K, Fotteler S, Medgyesi D
Life Sci Alliance. 2021; 4(11).
PMID: 34526379
PMC: 8473724.
DOI: 10.26508/lsa.202101084.
Bruton's Tyrosine Kinase and Its Isoforms in Cancer.
Wang X, Kokabee L, Kokabee M, Conklin D
Front Cell Dev Biol. 2021; 9:668996.
PMID: 34307353
PMC: 8297165.
DOI: 10.3389/fcell.2021.668996.
Myeloma Bone Disease: A Comprehensive Review.
Mukkamalla S, Malipeddi D
Int J Mol Sci. 2021; 22(12).
PMID: 34201396
PMC: 8227693.
DOI: 10.3390/ijms22126208.
Insights into evolutionary interaction patterns of the 'Phosphorylation Activation Segment' in kinase.
Ahiri A, Garmes H, Podlipnik C, Aboulmouhajir A
Bioinformation. 2019; 15(9):666-677.
PMID: 31787816
PMC: 6859708.
DOI: 10.6026/97320630015666.
T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia.
Xia S, Liu X, Cao X, Xu S
Cell Mol Immunol. 2019; 17(10):1042-1052.
PMID: 31431692
PMC: 7608443.
DOI: 10.1038/s41423-019-0270-9.
Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma.
Liu K, Guo J, Liu K, Fan P, Zeng Y, Xu C
EBioMedicine. 2018; 36:196-208.
PMID: 30268834
PMC: 6197714.
DOI: 10.1016/j.ebiom.2018.09.034.
Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.
Chong I, Aronson L, Bryant H, Gulati A, Campbell J, Elliott R
Gut. 2017; 67(10):1780-1792.
PMID: 28830912
PMC: 6145286.
DOI: 10.1136/gutjnl-2017-314408.